Development of the Effectiveness of Rehabilitation Tools for Neurovisual Disorders in Patients With Posterior Cortical Atrophy

NCT ID: NCT04041089

Last Updated: 2023-03-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-02

Study Completion Date

2022-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Posterior cortical atrophy (PCA) is manifested by neuro-visual disorders that alter the spatial location of objects, their manipulation and/or recognition. Its etiology is most often neurodegenerative, with a major impact on the autonomy and mood of patients and their families. Few studies have focused on non-medication management of these disorders.

The present study thus has a double objective: the development of a complete tool to work on the recognition, localization and/or manipulation of objects; and the evaluation of the effectiveness of this type of management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Posterior Cortical Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recognition of objects

Patients will do the therapy in the following order: object location, object manipulation and object recognition

Group Type EXPERIMENTAL

Recognition of objects

Intervention Type BEHAVIORAL

* Name of shapes / colors / images / objects
* Classification of shapes / colors / images / objects

Location of objects

Patients will do the therapy in the following order: object recognition, object location, and object manipulation

Group Type EXPERIMENTAL

Location of objects

Intervention Type BEHAVIORAL

* Search for frequent/rarse targets among distractors sharing one or more characteristics with the target
* Hit/catch a stationary/mobile target as quickly as possible

Manipulation of objects

Patients will do the therapy in the following order: object manipulation, object recognition and object location

Group Type EXPERIMENTAL

Manipulation of objects

Intervention Type BEHAVIORAL

* Storage of shapes/objects
* Use of everyday objects (pen, cutlery, etc.)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recognition of objects

* Name of shapes / colors / images / objects
* Classification of shapes / colors / images / objects

Intervention Type BEHAVIORAL

Location of objects

* Search for frequent/rarse targets among distractors sharing one or more characteristics with the target
* Hit/catch a stationary/mobile target as quickly as possible

Intervention Type BEHAVIORAL

Manipulation of objects

* Storage of shapes/objects
* Use of everyday objects (pen, cutlery, etc.)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>50 years old
* Male or Female
* Patients with a diagnosis of PCA according to the criteria of Tang-Wai et al (2004)
* MMS\>15
* Voluntary, written and informed consent of the patient himself or its legal representative (guardian/curator), with oral consent of the patient in all cases
* Anti-Alzheimer's and psychotropic treatments stable for one month, if taken by the patient
* Affiliation to a social security system

Exclusion Criteria

* Uncorrected visual disorders with non-degenerative etiology (AV\<0.5)
* Person under the protection of justice
* Pregnant women (a pregnancy test will be performed in premenopausal women)
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nice

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MOUTON Aurélie, Ph

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Universitaire de Nice

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Claude Pompidou - Centre Mémoire de Ressources et de Recherche du CHU de Nice

Nice, Alpes-Maritime, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-AOI-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.